UAE's Technology Innovation Institute Launches Open-Source "Falcon 40B" Large Language Model for Research & Commercial Utilization
25.5.2023 12:47:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today strengthened its growing international influence in the field of artificial intelligence by announcing that "Falcon 40B," the UAE's first large-scale AI model, is now open source for research and commercial use. This pioneering move demonstrates Abu Dhabi's commitment to fostering collaboration across sectors and driving advancements in generative AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005043/en/
"Falcon 40B," the UAE's first large-scale AI model, is now open source for research and commercial use. (Photo: AETOSWire)
Falcon, a foundational large language model (LLM) with 40 billion parameters, trained on one trillion tokens, grants unprecedented access to researchers and small and medium-sized enterprise (SME) innovators alike. TII is providing access to the model’s weights as a more comprehensive open-source package, with the aim of enabling access to powerful LLM capabilities, promoting transparency and accountability, and supporting innovation and research in the field.
In the current AI ecosystem, developers are finding LLMs that provide access to model weights more appealing due to the enhanced capabilities they offer for fine-tuning compared to those without. While the majority of LLMs have granted exclusive licenses solely to non-commercial users, TII has taken a key stride in offering researchers and commercial users access to the Falcon 40B LLM.
In conjunction with the release of Falcon 40B as an open-source model, TII has launched a call for proposals, inviting scientists, researchers, and visionaries who are enthusiastic about harnessing the potential of the foundation model. They are encouraged to contribute their innovative ideas and leverage the model to build inspiring use cases or explore further possibilities for its application to cover areas like engineering, healthcare, sustainability, coding, and much more.
As an incentive for exceptional research proposals, selected projects will receive “training compute power” in the form of investment, enabling innovators to leverage robust computational resources for accelerated data analysis, complex modeling, and new discoveries. This support will nurture and accelerate the development of novel ideas, providing the necessary resources to turn them into impactful AI solutions with commercial viability and societal benefits.
VentureOne, the commercialization arm of ATRC, will facilitate computation power to productize the most innovative solutions.
"Making Falcon 40B open source represents a critical milestone in our commitment to fostering AI innovation," said H.E.Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC). "We are disrupting LLM access and enabling researchers and entrepreneurs to come up with the most innovative use cases. We will further support these submissions with computation power as funding through VentureOne, helping to advance a thriving research ecosystem.”
Falcon, first unveiled in March 2023, showcased exceptional performance and underscored the UAE's commitment to technological progress. Based on Stanford University’s HELM LLM benchmarking tool, Falcon 40B outperformed its renowned counterparts in utilizing significantly less training compute power. With only 75 percent of the training compute of OpenAI's GPT-3, 40 percent of DeepMind's Chinchilla AI, and 80 percent of the training compute of Google's PaLM-62B, the tool substantiated TII's commitment to advancing developments in generative AI.
Dr. Ray O. Johnson, CEO of TII, said: "Computing power plays a pivotal role in expediting AI system training and enabling faster implementation of use cases. As the new fuel that drives technological innovation, the move to offer such support will be game-changing in enhancing the capabilities of innovators, and enabling them to push the boundaries of their projects to achieve remarkable advancements."
Falcon 40B is a breakthrough led by TII’s AI and Digital Science Research Center (AIDRC). The same team also launched NOOR, the world’s largest Arabic NLP model last year, and is on track to develop and announce Falcon 180B soon.
Dr. Ebtesam Almazrouei Director, AI Cross-Center Unit, TII, said: “The open-source release of Falcon 40B, 7.5B, and 1.3B parameter AI models and our high-quality REFINEDWEB dataset, exemplifies the profound scientific contributions of the UAE. With each breakthrough, we defy limitations, reshape the realm of possibilities, and pave the way for collaborative efforts with transformative impact."
The UAE recently moved up five places to rank as the top Arab country and the 37th out of 166 countries in the UN Frontier Technologies Readiness Index 2023. Complementing a long list of progressive technology milestones, the open-source generative AI model is set to boost the UAE’s credentials as a mainstream AI player.
If you are interested in accessing the Falcon AI models or submitting for the use case call for proposal, we invite you to visit FalconLLM.TII.ae. Falcon LLMs open sourced to date, will be made available under a license built upon the principles of open-source Apache 2.0 software, which allows for a wide range of free use.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005043/en/
Contact information
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
